Life science business process outsourcing (BPO) is one of the most lucrative industries in the healthcare sector. Constantly rising pricing pressure and increasing competition is compelling pharmaceutical and medical device companies to strategically reduce their operational costs and in turn benefit from higher profits. This has led to an increasing demand for contract manufacturing outsourcing (CMO) and contract research outsourcing (CRO) services. Asia and Latin America are the most attractive markets for CMO and CRO, owing to low costs of production and research activities performed here.
Download PDF Brochure Of This Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/24
The global life sciences BPO market is driven by factors such as increasing cost of research and development (R&D), growing price pressures, and increase in investments by pharmaceutical and medical devices companies in emerging economies such as India, China, Brazil, and South Africa. Pharmaceutical and medical device companies are adopting inorganic growth strategies to expand their business and reduce their Capital Expenditure (CAPEX) and Operation Costs (OPEX). However, outsourcing certain services to different CMO and CRO companies located in other countries is a challenge for the outsourcing company to monitor and follow a particular set of guideline for product approval pertaining to regulatory filings, clinical trials and medical writing. Collaborative efforts among various stakeholders of the ecosystem is analyzed to benefit the life science BPO industry in the long run.
This report segments the life sciences BPO market on the basis of service type and end user. On the basis of service type, the global life sciences BPO market is analyzed for medical device outsourcing, pharmaceuticals outsourcing and regulatory information. The end users covered in the report are healthcare providers and healthcare payers.
Patent expirations to boost the prospects for life sciences BPO market
According to UBM India Pharma Publication, over US$ 40 billion worth of drug are expected to be off-patent in the U.S. by 2017. Also, in 2014, utilization of generic drugs resulted in savings of around US$ 254 billion in the U.S. This trend is anticipated to increase further with more patent expirations in the near future. This factor coupled with the advent of biosimilars is projected to favor the growth of life sciences BPO market over the forecast period.
India home to second-highest number of U.S. FDA approved manufacturing facilities, an attractive proposition for India’s life sciences BPO market
Demand for contract manufacturing and contract research services in Asia is high, mainly due to large number of FDA approved drug manufacturing plants in this region. According to the UBM India Pharma Publication report of 2015, Indian accounts for 22% of the overall U.S. FDA approved drug manufacturing facilities globally. Moreover, dynamics such as wide availability of highly trained professionals, cheap labor, large patient pool, and easy availability of subjects for clinical trials are positioning Asia Pacific as a major life sciences BPO market. The life sciences BPO market in this region is expected to expand at a CAGR of 16.6% during the forecast period.
Uncertainty and differences in government regulations to increase demand for regulatory outsourcing services
Healthcare companies are subject to highly uncertain regulations that change according to country and changing government priorities. For instance, Section 3d of the Indian Pharma Act does not approve any new drug that is an altered form of a known molecule and not representing an improved efficacy over the existing molecule. While this drug is approved in the U.S., U.K, Australia and other countries. Dismissal of such patent applications discourages investment in countries with high growth potential. Also, mandatory licensing and patent ever-greening strategies further makes regulatory filing in a country more complex. Hence, healthcare companies hire regulatory experts of the respective countries to execute the regulatory process smoothly in that particular country.
Import and distribution of drug or medical devices in several countries require regulatory clearance that is efficiently managed by life science BPO companies. This enables pharmaceutical, biotech and medical device companies to focus on their core activities such as research, marketing, distribution agreements, and increasing product availability. The regulatory information segment is expected to grow swiftly to reach US$ 35 billion by 2024, on account of increasing abbreviated new drug application (ANDA) filings and growing interest in biosimilars.
Buy Now This Report: https://www.coherentmarketinsights.com/insight/buy-now/24
Key companies covered as a part of this study include Anthelio Healthcare Solutions, Accenture plc, Cognizant Technology Solutions, Catalent, Inc., Covance, Inc., Boehringer Ingelheim GmbH, Genpact Limited, Lonza Group, PAREXEL International Corporation and Quintiles Transnational Corporation.
This post was originally published on Trading Herald